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A B S T R A C T
Stavudine is an anti-AIDS drug widely used to prevent HIV transmission from pregnant mothers to the fetuses in
underdeveloped countries for its low price. However, there is still a controversy on whether stavudine affects
embryo development. In the current study, embryotoxicity of stavudine was evaluated using cultured mouse
embryos with the concentrations: 5, 10, 15 μM and vehicle control. The data indicated that the effect of sta-
vudine was dose-dependent at early neurogenesis. Stavudine exposure reduced somite numbers, yolk sac dia-
meter, crown-rump length, and increased the rate of embryonic degeneration compared with the control. We
chose the lowest but clearly toxic concentration: 5 μM to investigate the molecular mechanisms of the damage.
At the molecular level, stavudine produced DNA damage, increased the levels of the phospho-CHK1 and cleaved-
caspase-3, and decreased the expression level of proliferating cell nuclear antigen. These changes indicated that
stavudine caused a coordinated DNA damage response, inhibited cell proliferation, and induced apoptosis in the
embryos. Collectively these results suggest that stavudine exposure disturbs the embryonic development, and its
use in pregnant mothers should be re-examined.
1. Introduction
Antiretroviral therapy during pregnancy has dramatically reduced
the rate of mother-to-child transmission of HIV (Warszawski et al.,
2008). However, the number of HIV-infected pregnant women has in-
creased, which results in an increase in the number of babies who have
been exposed in utero to antiretroviral therapy. Tenofovir is an effective
nucleoside reverse transcriptase inhibitor with low toxicity
(Easterbrook et al., 2014). It is widely used as an anti-HIV drug.
However due to its relatively high cost, 3–7 million patients in South
Africa are not receiving this treatment. Instead, it was proposed that
stavudine be used as a low cost alternative (Persad and Emanuel, 2016).
Consequently, stavudine-based anti-HIV therapy is widely used as a first
line regimen in low- and middle-income countries (Venter et al., 2018).
Yet, it remains uncertain whether stavudine exposure affects the growth
and development of the embryo.
As a nucleoside reverse transcriptase inhibitor, stavudine has been
used to treat HIV infection since 1994. It is generally recommended for
prevention after a needle-stick injury or other potential exposures
(Huang et al., 1992). Stavudine blocks HIV replication by undergoing
intracellular phosphorylation and inhibiting HIV reverse transcriptase
by causing DNA chain termination (Huang et al., 1992). Stavudine also
appears to cause significant side effects, especially to embryo devel-
opment. Toltzis et al. reported that stavudine induced embryotoxicity in
the whole-embryo culture system in the blastocyst stage (Toltzis et al.,
1994). Exposure to stavudine-based HIV therapy in the first trimester of
pregnancy resulted in an increased rate of preterm birth, delayed lan-
guage, and other developmental concerns (Van Dyke et al., 2016).
Chappuy et al. observed that the concentrations of nucleoside analogue
reverse transcriptase inhibitors were higher in the amniotic fluid than
in maternal plasma (Chappuy et al., 2004). Thus there is a need to
investigate whether the high amniotic fluid nucleoside analogue
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reverse transcriptase inhibitor concentrations have an effect on the
development of fetus. Several other studies have also suggested that
stavudine affects embryonic development, causing stillbirth, low birth
weight (Bostan et al., 2010; Barreto et al., 2004), language problems
(Divi et al., 2007) and neurodevelopmental defects (Stammberger et al.,
1989). In contrast, other studies reported conflicting conclusions on the
embryo toxicity of stavudine. Price et al. found that ddI/Stavudine
combinations were not associated with developmental toxicity or ad-
verse drug interactions in pregnant mice (CD1) (Price et al., 2006). The
lack of developmental toxicity is confirmed by the results of Liu et al.
(Liu et al., 2014) and Salminskaia et al. (Salminskaia, 2013).
The controversy may be more consequential considering that sta-
vudine is a commonly substituted drug (35.5 %) in Africa and under-
developed countries. While birth defects (Seidahmed et al., 2014) due
to HIV drug use would bring a heavy burden to the families in any
society (Luteijn et al., 2014), the effects would be even more devas-
tating in economically and medically deprived societies. Thus, it is
urgent to clarify the impact of stavudine on embryonic growth and
development.
Embryotoxicity studies require a careful evaluation of the em-
bryonic development and a precise estimation of the morphological
differentiation of the embryo. Such studies often face two major pro-
blems. The first issue is how to remove maternal effects. It is sometimes
difficult to distinguish the maternal effects from the drug effects on
embryo development, as the maternal medical and metabolic condi-
tions can sometimes be confused with the effects of drugs. The second
issue is defining the stage of embryonic development. Each embryo may
have its own temporal and spatial pattern of development. Meanwhile,
there may be considerable individual variations in the reaction to sta-
vudine. To overcome these issues, mouse embryos may be an appro-
priate model for studying embryotoxicity. Using whole embryo culture
can remove the maternal effects and accurately define the embryonic
developmental stage (Kulkeaw et al., 2009). The teratogenic effects on
embryo growth and development can be accurately determined, with a
well-defined scoring system for quantifying the development of mor-
phological features. Whole embryo culture is visual (Pryor et al., 2012),
easy to operate, and convenient for elucidating the mechanism of
toxicity (Dunlevy et al., 2006).
In this study, we investigated the effects of stavudine on embryo
growth and development using the whole embryo culture system. The
results reveal that stavudine exposure results in extensive develop-
mental abnormalities in mouse embryos by causing DNA damage, in-
hibiting embryonic cell proliferation and inducing cell apoptosis. This
study provides further confirmation for the detrimental effects of sta-
vudine on embryonic development and suggests a mechanism by which
stavudine exerts such effects.
2. Materials and methods
2.1. Animal treatments
All procedures involving animal handling were approved by Animal
Care and Use Committee of Shanxi Medical University. All of the ex-
periments were carried out in accordance with the approved guidelines
by Shanxi Medical University. C57BL/6 mice (11400500030643, 9–10
weeks, 18–23 g) were housed in specific pathogen-free (SPF) cages at
an approved facility on a 12 h light/dark cycle and with controlled
temperature (22℃) and humidity (40–60 %). Mouse embryos at GD8.5
(Causeret et al., 2016) were cultured under sterilized condition at 37℃
for 48 h in heat-inactivated rat serum (Tuntland et al., 1999). Stavudine
was bought from MCE (Med Chem Express) and the catalogs number
was # 3056-17-5. For the growth of embryos, we choose rat serum as
the dissolvent to enhance the reliability of the experiments. Stavudine
power was added to rat serum and completely dissolved at a final
concentration of 1 mM for the stock solution, which was stored at−80
°C. Working solution at concentration of 5, 10, and 15 μM were freshly
made from stock solution. At the end of culture, embryos were quan-
titatively assessed by the scoring system as Van Maele-Fabry described
(Van Maele-Fabry et al., 1993). The yolk sac circulation, heart, caudal
neural tube, fore-, mid-, hindbrain, otic system, optic system, branchial
bars, forelimb, hindlimb and somites were separately scored. In addi-
tion, we measured and recorded yolk sac diameter, the crown-rump
length, and the rate of degeneration of deformity. The control and
stavudine-treated embryos were collected for subsequent experiments.
2.2. Hematoxylin and eosin (H&E) staining
Embryos were fixed in cold 4% formalin, dehydrated in gradient
alcohol, cleared in xylene, embedded with paraffin, cut into 3 μm-thick
sections, stained with hematoxylin and eosin (H&E) and observed under
a light microscope.
2.3. TUNEL analysis
DNA breaks were evaluated by terminal deoxynucleotidyl trans-
ferase (TdT) dUTP nick-end labeling (TUNEL assay). Procedures were
performed using the In Situ Cell Death Detection Kit (Roche,
Mannheim, Germany). In brief, formalin-fixed and paraffin-embedded
embryonic tissues of control and stavudine-treatment embryos were cut
into 3-μm thick slices, which were incubated with terminal deox-
ynucleotidyl transferase and dUTP. 3, 3'-Diaminobenzidine was used for
the color development. The TUNEL-positive cells were presented as
dark brown and counted under light microscope in six equal-sized fields
which were randomly chosen, and the data were presented as
mean± SD.
2.4. Proliferation and apoptosis analysis
Immunohistochemistry was performed as described previously
(Liang et al., 2018). Cleaved caspase-3 and proliferating cell nuclear
antigen (PCNA) were immunohistochemically stained in embryonic
tissues. The slides were incubated with primary rabbit antibodies
against cleaved caspase-3 (1:200, #9661, Cell Signaling Technology,
USA), or PCNA (1:50, #92729, Abcam, UK), followed by goat anti-
rabbit secondary biotinylated antibodies (Zhongshan Golden Bridge,
Beijing, China). The positive signals were visualized by DAB (Zhong-
shan Golden Bridge, Beijing, China) under the microscope at 100 times
magnification. We randomly chose three different visual areas within
the same regions of each section and counted the positive cells.
2.5. Western blot analysis
Standard Western blotting (Liang et al., 2018) assay was used to
analyze the levels of protein p-CHK1, cleaved caspase-3 and PCNA.
Briefly, proteins (30 g) from each sample were fractionated by SDS-
PAGE and transferred onto the PVDF membrane. The primary anti-
bodies used in the immunoblot were anti-phospho-CHK1 (Ser345) (p-
CHK1, 1:1000, #2341S, Cell Signaling Technology, USA), anti-cleaved
caspase-3 (Asp175) (1:1000, #9661, Cell Signaling Technology, USA),
anti-PCNA (EPR3822) (1:1000, #92729, Abcam, UK), anti-beta actin
(1:1000, ZSGB-BIO, China), and anti-GAPDH (sc-25778, Santa Cruz
Biotechnology, TX USA). Then the membrane was incubated in 5% non-
fat milk containing HRP-conjugated secondary antibody (1:5000) for 1
h. Signals were detected by ECL Chemiluminescent kit (Millipore) and
analyzed with image J software.
2.6. Statistical analysis
All quantitative data are expressed as mean± SD. Statistical ana-
lyses were performed using SPSS13.0 (SPSS Inc., Chicago, IL, USA)
software. We tested results by ANOVA for overall significance in
parametric growth measurements: yolk sac diameter, crown and hip
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length, embryo degeneration rate, and somite number, and Bonferroni
method was adjusted for multiple comparisons of stavudine treated
serums versus control.The data of PCNA, Tunel, CC3 and Western Blots
were tested by t-test and P values less than or equal to 0.05 were sig-
nificant.
3. Results
3.1. Morphological abnormalities in stavudine-treated embryos cultured for
48 h
To evaluate the effect of stavudine on embryonic development, E8.5
embryos were cultured for 48 h in the presence of 0, 5, 10, and 15 μM
stavudine. We evaluated the potential detrimental effects of stavudine
treatment on morphological and developmental parameters of murine
embryos (Van Maele-Fabry et al., 1993) (Fig. 1). We observed general
growth retardation in stavudine-treated embryos including retarded
yolk sac diameter and reduced crown-rump length. The morphological
and developmental parameters of embryos were assessed by a scoring
system as previously described. The development of the control em-
bryos was basically consistent with what Van Maele-Fabry described
(Van Maele-Fabry et al., 1993) (Fig. 1A-H). Significant differences in
embryo morphology were observed between stavudine-treated groups
and the control group (Fig. 1A-D). The number of somites, crown-rump
length, and Yolk sac diameter between embryos exposed to 0, 5, 10, and
15 u M Stavudine decreased progressively with the increase in stavu-
dine concentration, while the percentage of the embryo degeneration
increased (Fig. 1E-H). Embryos treated with 5, 10, and 15 μM stavudine
displayed lower total morphological scores compared with the control
embryos (Figs. 1 and 2). In the 15 μM stavudine treatment, embryos
displayed the lowest total morphological scores and many develop-
mental parameters could not be detected, such as the hind-, mid-
forebrain, otic vesicle, optic vesicle and so on.
The development of most organs was negatively affected by stavu-
dine treatment in a concentration dependent manner. The results of
dorsal-ventral flexure (embryo turning) showed a significant decrease
in 5, 10 and 15 μM stavudine-treated embryos compared with the
control embryos (Fig. 2). The control embryos completed turning, and
appeared dorsally convex with spiral torsion, while embryos treated
with 5 μM stavudine became C-shaped and appeared dorsally convex
(Fig. 2). The embryos treated with 10 μM stavudine were still ventrally
convex, and embryos treated with 15 μM stavudine almost fully
Fig. 1. Effect of stavudine-treatment on the morphology in embryos cultured for 48 h.
A-H showed embryos cultured in the presence of stavudine in concentrations of 0, 5, and 10 μM under dissecting microscope. A, images of the intact yolk sac in low
magnification (scale bar 1 mm). B, embryos with the intact yolk sac in high magnificationyolk sac (white arrow) and ectoplacental cone (black arrow) (scale bar =
300 μm). C, yolk sac and ectoplacental cone were removed from embryos (scale bar =200 μm). D, somites (short and black arrow) were decreased in a concentration-
dependent manner (scale bar =200 μm). E, F, G, and H quantification of the percentage of embryonic degeneration, Yolk sac diameter, crown-rump length and
somites in embryos exposed to 0, 5, 10 and 15 μM Stavudine. E-H: The overall significance in parametric growth measurements was tested by ANOVA. Bonferroni
method were adjusted for multiple comparisons of stavudine-treated serums versus control ***p ≤ .001, **p ≤ .01, *p ≤ .05; Student's t tests. n = 17.
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undergone degeneration. Developmental abnormalities in the neural
tube and the heart were also observed. Developmental parameters of
the caudal neural tube decreased in the 5, 10 and 15 μM stavudine-
treated embryos (Fig. 2) compared with the control embryos. A sig-
nificant abnormalities of heart development was observed at 5 and 10
μM stavudine-treated embryos. The hearts in the 15 μM stavudine-
treated embryos had no heart beat and stayed in 4–6 somites stage,
while the normal embryos had 27–30 somites and four chambers. Heart
appeared atrium commune and ventriculus communis in 5 μM stavu-
dine-treated embryos. There was just a beating convoluted cardiac tube
in 10 μM stavudine-treated embryos (Figs. 1 and 2).
The brain, including fore-, mid- and hindbrain, had also significant
growth abnormalities in stavudine-treated embryos in a concentration-
dependent manner compared to control embryos. The brain in the 15
μM stavudine-treated embryos stopped developing. In the hindbrain,
the neural folds of the 10 μM stavudine-treated embryos also just had a
V-shape in tangential view. The 5 μM stavudine-treated embryos had a
partially fused rhombencephalon and a formed anterior neuropore with
open folds, while the control groups had a completely closed anterior
neuropore and a formed rhombencephalon with transparent roof of the
4th ventricle. In the middbrain, the neural folds of the 10 μM stavudine-
treated embryos just had a V-shape in tangential view. The 5 μM sta-
vudine-treated embryos had a partially fused mesencephalic folds
(Fig. 1), while the control groups had a completely fused mesence-
phalon and a visible division between mesencephalon and dience-
phalon. In the forebrain, the 10 μM stavudine-treated embryos just had
a V-shaped neural tube in tangential view. The 5 μM stavudine-treated
embryos had partially fused prosencephalic folds while the control
groups had completely fused and visible telencephalic evaginations
(Fig. 2).
The four branchial bars are visible in the control embryos, while the
scores were lower in the 5 and 10 μM stavudine-treated embryos. The
development of the mandibular, olfactory, and optic vesicle, otic vesicle
in the 5 μM stavudine-treated embryos was similar to the control em-
bryos, but significant developmental retardation was found in the 10
and 15 μM stavudine-treated embryos (P<0.01). The result showed a
significant degeneration rate (44.4 %) in the 15 μM stavudine treated-
embryos, while the survived embryos displayed abnormal development
and stunted organs (Fig. 2). We chose the lowest but clearly toxic
concentration: 5 μM to investigate the molecular mechanisms of the
damage.
3.2. Anatomical abnormalities in stavudine-treated embryos cultured for 48
h
In order to identify anatomical change, control and 5 μM stavudine-
treated embryos were serially sectioned and subjected to histological
analysis (n = 3). The development of the control embryos was similar
to that described by Copp (Copp, 2005). There are significant differ-
ences in the brain tissue structure between the control and stavudine-
treated embryos (Fig. 3A–G). The stavudine-treated embryos had rela-
tively flat and narrow midbrain bubbles (Fig. 3B), smaller hindbrain
vesicles, and more thinker roof plates of hindbrain (Fig. 3C). Neuroe-
pithelial cells were loosened, and the wall of lumen was uneven, with
some cells shrunken and detached in stavudine-treated embryos. We
detected the first branchial arch, heart, somites, and tail in control
embryos (Fig. 3D-G). In contrast, the stavudine-treated embryos lacked
a thin and long tail compared with the control embryos (Fig. 3G).
3.3. TNEL in stavudine-treated embryos cultured for 48 h
Considering the significant developmental abnormalities in the
Fig. 2. Morphological scoring of embryos cultured for 48 h in stavudine-treatment by Van Maele-Fabry. Morphological scores of embryos treated with 0, 5, and 10
μM stavudine in the development of the brain, heart, neural tube, flexion, somites, and caudal neural tube. The 15 μM stavudine-treated embryos displayed the lowest
total morphological scores and many developmental parameters could not be detected, such as the hind-, mid- forebrain, otic vesicle, optic vesicle and so on. The
overall significance in parametric growth measurements was tested by ANOVA. Post hoc tests of stavudine-treated serums versus control. ***p≤ .001, **p≤ .01, *p
≤ .05; Student's t tests. n = 17.
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stavudine-treated embryos, we assessed if the drug caused apoptosis by
the terminal deoxynucleotidyl transferase (TdT) dUTP nick-end la-
beling (TUNEL) analysis. TUNEL-positive cells were significantly higher
in stavudine-treated embryos than in the controls. In the controls, some
TUNEL-positive cells were located in the fore and hindbrain. Increased
amount of TUNEL-positive cells were seen throughout the fore and
hindbrain in embryos exposed to 5 μM stavudine (Fig. 4A-C). We also
found a significant increase in TUNEL positive cells in the 1 st branchial
arch, the somites at the level of forelimb, and the tail in stavudine-
treated embryos (Fig. 4D, F, G, andH P<0.05), while a modest in-
crease was seen in the midbrain compared with the controls and had no
significant statistis (Fig. 4E, P> 0.05). These observations indicated
that stavudine treatment caused significant and widespread apoptosis
in the embryos (Fig. 4H, P<0.05).
3.4. Effects on cell proliferation in stavudine treatment embryos cultured for
48 h
To explore the cellular basis of the developmental abnormalities, we
investigated the effects of stavudine on cell proliferation in the em-
bryos. Cell proliferation was assessed by determining the expression
levels of proliferating cell nuclear antigen (PCNA) using
immunohistochemical staining. We found a large number of PCNA
positive cells in the control embryos, but much reduced numbers in the
5 μM stavudine-treated embryos (Fig. 5A–G). The decrease of PCNA-
positive cells in in fore-, midbrain, heart and caudal neural tube sug-
gested that stavudine inhibited cell proliferation (Fig. 5H, P<0.05).
3.5. Effects of stavudine treatment on cell apoptosis in embryos cultured for
48 h
To further determine if stavudine treatment induced apoptosis in
mouse embryos, the immunohistochemically stained for the level of
cleaved caspase-3 (Fig. 6A–G). Stavudine increased cleaved caspase-3
positive cells in the fore-, mid-, hindbrain, heart, somites and caudal
tube (Fig. 6A-C, P<0.05), heart, somites, and tail (Fig. 6E, F, G, H,
P< 0.05), but did not significantly change the cleaved caspase-3 level
in the 1 st branchial arch region (Fig. 6D, P>0.05). The widespread
increases in the cleaved caspase-3 levels suggested that 5 μM stavudine
caused apoptosis in a large number of tissues (Fig. 6H, P<0.05).
Fig. 3. Anatomical abnormalities of 5 μM stavudine-treated embryos cultured for 48 h. A-G showed structures of the forebrain, midbrain, hindbrain, heart, somites,
branchial bars, and tail from normal embryos and 5 μM stavudine-treated embryos, n = 3, Scale bars indicated 100 μm.
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3.6. Effects of stavudine on the levels of phospho-CHK1, cleaved caspased-3
and PCNA in embryos cultured for 48 h assessed by Western blot
To confirm the effects of 5 μM stavudine treatment on embryonic
PCNA and cleaved caspase-3 levels observed in immunohistochemical
staining, we further determined the expression levels of these and DNA
damage response coordinating protein kinase CHK1 by Western blots
(Fig. 7). Phospho-CHK1 (p-CHK1) is a critical protein kinase that gets
activated by phosphorylation in response to DNA damage, which in
turn coordinates DNA repair, cell cycle arrest and cell death. The results
showed that the level of p-CHK1 in 5 μM stavudine-treated embryos
was 2.37 times higher than in the control embryos (Fig. 7A-B,
*P<0.05). The protein level of cleaved caspase-3 in the 5 μM stavu-
dine-treated embryos was 1.24 times higher than in the control em-
bryos (Fig. 7C and D, *P<0.05). Furthermore, the protein level of
PCNA in the 5 μM stavudine-treated embryos decreased 22 % compared
to the control embryos (Fig. 7E and F, *P<0.05). These results
confirmed the immunohistochemical staining results, and further sup-
ported the conclusion that stavudine inhibited cell proliferation and
induced the cell death, combined with DNA damage.
4. Discussion
The major goal of this study was to determine the effects of stavu-
dine on the growth of embryo via the whole embryo culture platform.
The parameters of growth and development decreased in many tissues
and organs, including yolk sac diameter, somite numbers, turning, and
branchial bars, while the rate of deformities and degeneration increased
in the stavudine-treatment embryos. The study also provided new evi-
dence that stavudine caused DNA damage, induced apoptosis of em-
bryonic cells, and inhibited embryonic cell proliferation.
It is currently highly controversial if stavudine causes embryonic
abnormalities. The range of human peak serum stavudine concentration
is 3−10 μM when a patient is treated with clinically beneficial dose of
Fig. 4. Increased apoptosis in 5 μM stavudine-treated embryos cultured for 48 h. A-G, showed TUNEL results of forebrain, midbrain, hindbrain, heart, somites,
branchial bars, and caudal neural tube in normal embryos (white bar) and 5 μM stavudine-treated embryos (black bar). Scale bar indicate 100 μm. H, quantification
of the number of TUNEL positive cells 5 μM stavudine-treated embryos compared with controls. **p ≤ .01, *p ≤ .05; Student's t tests., n = 3.
R.-F. Ao, et al. Toxicology 439 (2020) 152443
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stavudine (Copp, 2005). The developmental anomalies induced by
stavudine observed in the current study are caused by similar stavudine
concentrations. The findings are consistent with the report by Toltzis
and coworkers (Toltzis et al., 1994) suggesting that sublethal pre-
blastocyst exposure to stavudine at 10 μM resulted in failure to develop
beyond the blastocyst stage, even though we used post-implantation
embryos, and they used pre-implantation embryos. The conclusion that
stavudine damaged the development of embryos (Bostan et al., 2010;
Barreto et al., 2004) is also supported by several other studies. How-
ever, Price et al. found that stavudine administered to pregnant CD1
mice by gavage had little effects on prenatal mortality, morphologic
anomalies, and fetal body weight (Price et al., 2006). This result was
confirmed by other similar studies by Liu et al. (2014) and Salminskaia
(2013). The controversy may be due to the difficulty to compare results
when the studies used different experimental set up (gavage feeding
versus embryo culture) and the effect of assessment method. In the
experiments with pregnant mice, it is not clear what concentration of
stavudine the embryos were exposed to, and what the maternal effects
were on the study. The various effects of the drug on embryo devel-
opment were also not directly measured. In contrast, the whole embryo
culture platform we used in the current study provided a more direct
and well controlled system for assessing the effects of stavudine on
embryo development. Our results demonstrated that when embryos
were directly exposed to stavudine, major developmental effects were
observed. The system also allowed us to determine the mechanism by
which stavudine exerted its effects: it caused extensive DNA damage,
inhibited cell proliferation and induced apoptosis.
A key unknown in mouse experiments and in patients is the con-
centration of stavudine the embryos are exposed to. The range of
human peak serum stavudine concentration is 3−10 μM when a patient
is treated with clinically beneficial dose of stavudine (Horton et al.,
1995). That is why we used the concentrations 5−15 μM in the current
study. However, it is unknown what concentration of stavudine human
embryos are actually exposed to in patients. A number of factors may
Fig. 5. Decreased proliferation in 5 μM stavudine-treated embryos cultured for 48 h. A-G, PCNA expression in the forebrain, midbrain, hindbrain, heart, somites,
branchial bars, and caudal neural tube in normal (white bar) and stavudine-treated (5 μM) embryos (black bar). Scale bars indicate 100 μm. H, quantification of the
number of PCNA positive cells in stavudine-treated and control embryos. **p ≤ .01, *p ≤ .05; Student's t tests., n = 3.
R.-F. Ao, et al. Toxicology 439 (2020) 152443
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affect the concentration of stavudine an embryo could be exposed to,
and it is not well understood how the physiological changes of preg-
nancy may impact the antiretroviral pharmacokinetics. For example,
Price et al. demonstrated that the stavudine internal concentration was
lower in pregnant women than in other adults (Price et al., 2006), while
Chappuy et al. (2004) indicated that stavudine is probably excreted
through fetal urinary. In contrast, the urinary of whole embryo culture
lacks the connection to the maternal system for excretion. Thus it is
possible that the embryos are actually exposed to lower levels of sta-
vudine, even though a patient have 3−10 μM stavudine in the serum. It
will be important to determine if there is a window of concentration of
stavudine that can have the anti-viral benefits without causing devel-
opmental abnormalities. The concentrations we used are in the same
ballpark as the concentration in the Chappuy study. With scarce phar-
macokinetic information unavailable, our study is only mechanistic.
Caution should be exercised in extrapolating such results directly and
quantitatively into patients. With that said, the mechanistic insights
gained in this study will likely guide our understanding how HIV
treatment may affect fetal development, at least qualitatively.
DNA instability during embryonic development would be expected
to cause birth defect (Green et al., 2010). The results of p-chk1 analysis
indicated that stavudine-treatment caused DNA damage in the embryos.
DNA damage triggers DNA repair mechanisms. When DNA damage fails
to be repaired, cell cycle will be stopped, and caspase-3 may be acti-
vated, which leads to apoptosis. Our findings suggested that the DNA
damage response coordinating protein kinase CHK1 was activated, and
active caspase-3 proteins was also markedly enhanced, and the number
of PCNA positive cells decreased in neuroepithelial cells in the stavu-
dine-treated embryos. These observations together would provide a
mechanistic explanation for the stavudine embryonic toxicity. Although
we have not yet investigated how stavudine causes DNA damage, it is
plausible that as a nucleoside analog, stavudine may be recognized by
some mouse or human DNA metabolic enzymes to interfere with DNA
metabolism, resulting in DNA damage.
Fig. 6. Increased apoptosis in 5 μM stavudine-treated embryos cultured for 48 h. A-G, level of cleaved caspase-3 in forebrain, midbrain, hindbrain, heart, somites,
branchial bars, and caudal neural tube in normal (white bar) and stavudine-treated embryos (black bar). Scale bars indicate 100 μm. H quantification of the number
of cleaved caspase-3 positive cells in 5 μM stavudine-treated and control embryos. ***p ≤ .001 **p ≤ .01, *p ≤ .05; Student's t tests., n = 3.
R.-F. Ao, et al. Toxicology 439 (2020) 152443
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Morphogenesis of the nervous system is based on a complex inter-
play among cell proliferation, differentiation and apoptosis (Greene and
Copp, 2014). Increasing experimental evidence demonstrates that in-
creased apoptosis and decreased proliferation caused by folate dysme-
tabolism are associated with neural tube abnormalities (Pai et al.,
2015). Ke et al. concluded that apoptosis plays a crucial role in em-
bryonic development, especially for midline fusion and aortic arch
formation (Ke et al., 2018). Our results showed that DNA damage
caused by stavudine, increased apoptosis and decreased proliferation in
embryonic development. This imbalance is likely the underlying me-
chanism for the developmental abnormalities in stavudine-treated em-
bryos.
In conclusion, it is well established that antiretroviral therapy can
reduce the risk of passing the HIV infection from a mother to her child
(Aaron and Cohan, 2013). However, possible adverse effects of anti-
AIDS drugs on the development of the embryo are of great concern. Our
study sheds light on the potential adverse effects and the mechanisms of
such effects by stavudine. Perhaps the concentration of stavudine may
be different in WEC and human fetal exposed. A key piece of in-
formation we lack is how much stavudine the embryo would be exposed
to in a mother under HIV treatment. We wait with keen interest for such
data that will provide critical guidance to future research on both sta-
vudine toxicology and HIV treatment optimization.
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